Arbutus Biopharma Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 10, 2026, reporting a nine-month net income of $223,667 thousand and a third-quarter net income of $59,115 thousand.
Key Highlights
- Nine-month net income of $223,667 thousand: Compared to a net loss of $29,745 thousand for the same period in 2025, according to the filing.
- License revenue from Genevant of $179,373 thousand: Recognized in the nine months ended September 30, 2026, with no comparable amount in the prior-year period.
- Dividend income of $67,252 thousand: Recorded in the three months ended September 30, 2026, with no comparable amount in the prior-year quarter.
- Cash and cash equivalents of $264,191 thousand: As of September 30, 2026, up from $18,008 thousand at December 31, 2025.
- Obligation to repurchase shares of $230,000 thousand: Recorded as a current liability on the September 30, 2026 balance sheet, with no such balance at December 31, 2025.
- 153,292,826 common shares outstanding: As of November 6, 2026, as reported on the cover page of the filing.
Arbutus Biopharma Q3 2026: Genevant License and Dividend Income Drive Results
According to the filing, Arbutus Biopharma Corporation (NASDAQ:ABUS) reported total revenue of $180,439 thousand for the nine months ended September 30, 2026, compared to $13,032 thousand for the same period in 2025. The primary driver was license revenue from Genevant of $179,373 thousand, which the filing shows had no prior-year equivalent. For the three months ended September 30, 2026, total revenue was $299 thousand, compared to $529 thousand in the year-ago quarter.
The filing also disclosed $67,252 thousand in dividend income during the third quarter of 2026, which together with interest income of $2,370 thousand contributed to total other income of $69,609 thousand for that quarter. Research and development expenses declined to $2,617 thousand in Q3 2026 from $5,778 thousand in Q3 2025, while general and administrative expenses increased to $7,955 thousand from $3,044 thousand over the same periods. The company reported income from operations of $152,450 thousand for the nine-month period, compared to a loss from operations of $32,870 thousand in the prior-year nine-month period.
On the balance sheet, the filing shows total assets of $339,698 thousand as of September 30, 2026, versus $94,618 thousand at December 31, 2025. A new current liability labeled "Obligation to repurchase shares" of $230,000 thousand appears as of September 30, 2026. The stockholders' equity statement reflects that during Q3 2026 an "Obligation to repurchase shares, inclusive of transaction costs" of $237,949 thousand was recorded against additional paid-in capital. Issued and outstanding common shares were 199,275,907 as of September 30, 2026, up from 192,531,225 at December 31, 2025. Basic earnings per share for the nine months ended September 30, 2026 were $1.14, compared to a loss of $0.16 per share in the same period of 2025.
What Was Disclosed
Arbutus Biopharma's 10-Q for the nine months ended September 30, 2026 disclosed a swing to net income of $223,667 thousand, driven largely by $179,373 thousand in Genevant license revenue and $67,252 thousand in dividend income, alongside a $230,000 thousand share repurchase obligation on the balance sheet.



Please wait processing your request...